Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Methionine aminopeptidase from Staphylococcus aureus is an essential metalloenzyme responsible for the removal of N-terminal methionine from newly synthesized proteins, a crucial step in bacterial protein maturation. It acts as a dinuclear metalloprotease and typically functions as a mononuclear Fe2+-metalloprotease under physiological conditions. This enzyme’s activity is indispensable for bacterial life and virulence, making it a promising antibacterial drug target. Structural studies have led to potent inhibitors that target this enzyme specifically, and differences between bacterial and mammalian homologs have enabled efforts to develop selective antibacterial therapies.
Direct inhibition of the enzyme’s active site, usually by the formation of a stable transition-state analogue (uncleavable tetrahedral intermediates mimic amide bond hydrolysis and block function)
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Methionine aminopeptidase from Staphylococcus aureus (MetAP).